The Claim
In older men with coronary artery disease undergoing cardiac rehabilitation, 12 weeks of daily low-dose rapamycin (0.5–1.0 mg) was associated with a reduction in adipose tissue expression of p16 mRNA, a biomarker of cellular senescence, from 169 to 129 arbitrary units, suggesting a potential attenuation of tissue-level aging processes.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
Older guys with heart disease who took a low dose of a drug called rapamycin every day for 12 weeks showed signs that their body fat was aging more slowly.
See the scientific wording
In older men with coronary artery disease undergoing cardiac rehabilitation, 12 weeks of daily low-dose rapamycin (0.5–1.0 mg) was associated with decreased adipose tissue expression of p16 mRNA (from 169 to 129 arbitrary units), a marker of cellular senescence, suggesting possible reduction in tissue-level aging processes.
What the research says
1 studyThe study gave older men with heart disease a low dose of rapamycin for 12 weeks and found that a marker of cell aging in fat tissue went down, which matches what the claim says.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.